Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease (Q29037884)

autosomal dominant polycystic kidney disease

27 March 2017

main subject

0 references

autosomal dominant polycystic kidney

1 reference

Olivier Devuyst

0 references

0 references

0 references

Ron T. Gansevoort

1 reference

27 March 2017

Vicente E. Torres

1 reference

27 March 2017

Arlene B. Chapman

1 reference

27 March 2017

Jared J. Grantham

1 reference

27 March 2017

Eiji Higashihara

1 reference

27 March 2017

Ronald D. Perrone

1 reference

27 March 2017

Holly B. Krasa

1 reference

27 March 2017

John Ouyang

1 reference

27 March 2017

Frank S. Czerwiec

1 reference

27 March 2017

language of work or name

English

0 references

publication date

20 December 2012

1 reference

The New England Journal of Medicine

27 March 2017

published in

1 reference

27 March 2017

volume

367

1 reference

27 March 2017

issue

1 reference

27 March 2017

page(s)

2407-2418

1 reference

Developmental expression of urine concentration-associated genes and their altered expression in murine infantile-type polycystic kidney disease

27 March 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3760207

Random-effects models for longitudinal data

6 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3760207

Prediction of creatinine clearance from serum creatinine

6 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3760207

Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease.

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3760207

Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3760207

Tolvaptan inhibits ERK-dependent cell proliferation, Cl−secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3760207

Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3760207

Sirolimus therapy to halt the progression of ADPKD.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3760207

Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3760207

Oral tolvaptan is safe and effective in chronic hyponatremia

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3760207

Clinical practice. Autosomal dominant polycystic kidney disease

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3760207

Vasopressin directly regulates cyst growth in polycystic kidney disease

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3760207

Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3760207

Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3760207

Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3760207

Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3760207

OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3760207

Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3760207

Therapeutic potential of vasopressin V2 receptor antagonist in a mouse model for autosomal dominant polycystic kidney disease: optimal timing and dosing of the drug

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3760207

Everolimus in patients with autosomal dominant polycystic kidney disease.

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3760207

Sirolimus and kidney growth in autosomal dominant polycystic kidney disease

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3760207

Modification of the CKD epidemiology collaboration (CKD-EPI) equation for Japanese: accuracy and use for population estimates

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3760207

Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial.

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3760207

Comparison of methods for determining renal function decline in early autosomal dominant polycystic kidney disease: the consortium of radiologic imaging studies of polycystic kidney disease cohort

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3760207

Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3760207

Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat.

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3760207

Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease

26 November 2018

1 reference

12 December 2020

Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study)

1 reference

12 December 2020

The power to detect differences in average rates of change in longitudinal studies

1 reference

12 December 2020

Volume progression in polycystic kidney disease

1 reference

12 December 2020

Increased water intake decreases progression of polycystic kidney disease in the PCK rat

1 reference

12 December 2020

Autosomal dominant polycystic kidney disease

1 reference

12 December 2020

Rationale and Design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes) 3-4 Study

1 reference

12 December 2020

Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist

1 reference

12 December 2020

Identifiers

DOI

10.1056/NEJMOA1205511

2 references

27 March 2017

1 reference

1 reference

PubMed publication ID

23121377

1 reference